Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, a move aimed at bolstering its endocrinology and rare‑disease pipeline. The offer translates to $53 a share, roughly a 34% premium to Soleno’s closing price on April 2. Investors will watch how the combined portfolio expands treatment options in niche markets. The deal follows a year of strategic hires and late‑stage trial data that positioned Soleno as a valuable add‑on for Neurocrine’s growth agenda.

Financing the transaction will rely on Neurocrine’s cash reserves, while the company plans to fine‑tune its balance sheet with a modest tranche of pre‑payable debt. The approach preserves liquidity for ongoing R&D programs and signals confidence that the acquisition will be accretive once Soleno’s pipeline advances toward market entry.

Regulatory clearance is expected within 90 days, after which Neurocrine will integrate Soleno’s lead candidates into its commercial infrastructure. Shareholders of both firms stand to benefit from the combined expertise, and the deal underscores a broader trend of mid‑cap biotech firms consolidating to achieve scale in high‑cost therapeutic areas.

Following the announcement, Neurocrine’s stock rose about 6% in after‑hours trading, while Soleno’s shares jumped near the offer price. Analysts note the premium reflects Soleno’s promising asset base and the scarcity of comparable targets, suggesting the deal could set a benchmark for future biotech consolidations.